Trump Or Clinton? The U.S. Will Still Be Willing To Buy Good Pharmaceuticals, Says Actelion CEO
The CEO of a leading biopharmaceutical company has tried to reassure investors over upcoming U.S. elections, saying there won't be any change in demand for drugs regardless of who wins the race for the White House.
"If you bring to the patients innovative growth, good drugs which are going to help them, which are really going to make them feel better or live longer, the country - United States - is going to pay for these drugs and there are many systems in place which will allow that," Jean-Paul Clozel, the CEO of Swiss-based Actelion, told CNBC Thursday.
"If you bring to the patients innovative growth, good drugs which are going to help them, which are really going to make them feel better or live longer, the country - United States - is going to pay for these drugs and there are many systems in place which will allow that," Jean-Paul Clozel, the CEO of Swiss-based Actelion, told CNBC Thursday.